ABOUT US
CONTACT US
FAQ
PRIVACY POLICY
REFUND AND CANCELLATION
BLOGS
COMPANIES
REPORTS
0
U.S. (TOLL FREE)
+1 (315) 215-3225
Automative
0
U.S. (TOLL FREE)
+1 (315) 215-3225
Global HCC (Hepatocellular Carcinoma) Biomarker Market Research Report 2025
Published Date: September 2025
|
Report Code: QYRE-Auto-16M16719
Home | Market Reports | Health| Health Conditions| Cancer
Global HCC Hepatocellular Carcinoma Biomarker Market Research Report 2024
BUY CHAPTERS

Global HCC (Hepatocellular Carcinoma) Biomarker Market Research Report 2025

Code: QYRE-Auto-16M16719
Report
September 2025
Pages:84
QYResearch
Buy Now with 15% Discount
DESCRIPTION
TABLE OF CONTENT
TABLES & FIGURES
FEATURED COMPANIES
Fujifilm
Eli Lilly and Company
Fujirebio
Roche Diagnostics
Fapon Biotech
LabCorp
Thermo Fisher Scientific
Abcam
Bio-Techne
MyBioSource
RayBiotech
Cusabio
Elabscience Biotechnology
Abbexa

HCC (Hepatocellular Carcinoma) Biomarker Market Size

The global market for HCC (Hepatocellular Carcinoma) Biomarker was valued at US$ 892 million in the year 2024 and is projected to reach a revised size of US$ 1351 million by 2031, growing at a CAGR of 6.2% during the forecast period.

HCC (Hepatocellular Carcinoma) Biomarker Market

HCC (Hepatocellular Carcinoma) Biomarker Market

Hepatocellular carcinoma (HCC) is the seventh most common cancer diagnosis worldwide with high associated mortality. HCC is a unique malignancy, as it typically arises in the setting of chronic liver disease in particular cirrhosis, with competing risks of liver failure, contributing to its low 5-year survival rates of 18%–20%. More than half of worldwide HCC-related deaths occur in Asia, due to endemic hepatitis B (HBV) infection. HCC incidence is rising in many Western countries due to the rising prevalence of nonalcoholic fatty liver disease, alcohol-related liver disease, and hepatitis C (HCV)-related complications despite the availability of direct acting antiviral therapies. The search for biomarkers in hepatocellular carcinoma continues despite recent approvals for immune checkpoint inhibitor combinations, tyrosine kinase inhibitors [TKIs], and antiangiogenesic agents. Biomarkers can be either predictive or prognostic and the only biomarker that has been used clinically is the prognostic biomarker α-fetoprotein (AFP).
North American market for HCC (Hepatocellular Carcinoma) Biomarker is estimated to increase from $ million in 2024 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
Asia-Pacific market for HCC (Hepatocellular Carcinoma) Biomarker is estimated to increase from $ million in 2024 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
The global market for HCC (Hepatocellular Carcinoma) Biomarker in Hospitals is estimated to increase from $ million in 2024 to $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
The major global companies of HCC (Hepatocellular Carcinoma) Biomarker include FUJIFILM, Eli Lilly and Company, Fujirebio, Roche Diagnostics, Fapon Biotech, Labcorp, Thermo Fisher Scientific, Abcam, Bio-Techne, MyBiosource, etc. In 2024, the world's top three vendors accounted for approximately % of the revenue.
This report aims to provide a comprehensive presentation of the global market for HCC (Hepatocellular Carcinoma) Biomarker, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding HCC (Hepatocellular Carcinoma) Biomarker.
The HCC (Hepatocellular Carcinoma) Biomarker market size, estimations, and forecasts are provided in terms of and revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. This report segments the global HCC (Hepatocellular Carcinoma) Biomarker market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the HCC (Hepatocellular Carcinoma) Biomarker companies, new entrants, and industry chain related companies in this market with information on the revenues for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation

Scope of HCC (Hepatocellular Carcinoma) Biomarker Market Report

Report Metric Details
Report Name HCC (Hepatocellular Carcinoma) Biomarker Market
Accounted market size in year US$ 892 million
Forecasted market size in 2031 US$ 1351 million
CAGR 6.2%
Base Year year
Forecasted years 2025 - 2031
Segment by Type
  • Alpha-fetoprotein (AFP)
  • Des-γ-carboxy Prothrombin (DCP)
  • Others
Segment by Application
  • Hospitals
  • Clinics
  • Others
By Region
  • North America (United States, Canada)
  • Europe (Germany, France, UK, Italy, Russia) Rest of Europe
  • Nordic Countries
  • Asia-Pacific (China, Japan, South Korea)
  • Southeast Asia (India, Australia)
  • Rest of Asia
  • Latin America (Mexico, Brazil)
  • Rest of Latin America
  • Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of MEA)
By Company FUJIFILM, Eli Lilly and Company, Fujirebio, Roche Diagnostics, Fapon Biotech, Labcorp, Thermo Fisher Scientific, Abcam, Bio-Techne, MyBiosource, RayBiotech, CUSABIO, Elabscience Biotechnology, Abbexa
Forecast units USD million in value
Report coverage Revenue and volume forecast, company share, competitive landscape, growth factors and trends

Chapter Outline

  • Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
  • Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
  • Chapter 3: Detailed analysis of HCC (Hepatocellular Carcinoma) Biomarker company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
  • Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
  • Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
  • Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
  • Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
  • Chapter 12: The main points and conclusions of the report.

FAQ for this report

How fast is HCC (Hepatocellular Carcinoma) Biomarker Market growing?

Ans: The HCC (Hepatocellular Carcinoma) Biomarker Market witnessing a CAGR of 6.2% during the forecast period 2025-2031.

What is the HCC (Hepatocellular Carcinoma) Biomarker Market size in 2031?

Ans: The HCC (Hepatocellular Carcinoma) Biomarker Market size in 2031 will be US$ 1351 million.

Who are the main players in the HCC (Hepatocellular Carcinoma) Biomarker Market report?

Ans: The main players in the HCC (Hepatocellular Carcinoma) Biomarker Market are FUJIFILM, Eli Lilly and Company, Fujirebio, Roche Diagnostics, Fapon Biotech, Labcorp, Thermo Fisher Scientific, Abcam, Bio-Techne, MyBiosource, RayBiotech, CUSABIO, Elabscience Biotechnology, Abbexa

What are the Application segmentation covered in the HCC (Hepatocellular Carcinoma) Biomarker Market report?

Ans: The Applications covered in the HCC (Hepatocellular Carcinoma) Biomarker Market report are Hospitals, Clinics, Others

What are the Type segmentation covered in the HCC (Hepatocellular Carcinoma) Biomarker Market report?

Ans: The Types covered in the HCC (Hepatocellular Carcinoma) Biomarker Market report are Alpha-fetoprotein (AFP), Des-γ-carboxy Prothrombin (DCP), Others

1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global HCC (Hepatocellular Carcinoma) Biomarker Market Size Growth Rate by Type: 2020 VS 2024 VS 2031
1.2.2 Alpha-fetoprotein (AFP)
1.2.3 Des-γ-carboxy Prothrombin (DCP)
1.2.4 Others
1.3 Market by Application
1.3.1 Global HCC (Hepatocellular Carcinoma) Biomarker Market Growth by Application: 2020 VS 2024 VS 2031
1.3.2 Hospitals
1.3.3 Clinics
1.3.4 Others
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Global Growth Trends
2.1 Global HCC (Hepatocellular Carcinoma) Biomarker Market Perspective (2020-2031)
2.2 Global HCC (Hepatocellular Carcinoma) Biomarker Growth Trends by Region
2.2.1 Global HCC (Hepatocellular Carcinoma) Biomarker Market Size by Region: 2020 VS 2024 VS 2031
2.2.2 HCC (Hepatocellular Carcinoma) Biomarker Historic Market Size by Region (2020-2025)
2.2.3 HCC (Hepatocellular Carcinoma) Biomarker Forecasted Market Size by Region (2026-2031)
2.3 HCC (Hepatocellular Carcinoma) Biomarker Market Dynamics
2.3.1 HCC (Hepatocellular Carcinoma) Biomarker Industry Trends
2.3.2 HCC (Hepatocellular Carcinoma) Biomarker Market Drivers
2.3.3 HCC (Hepatocellular Carcinoma) Biomarker Market Challenges
2.3.4 HCC (Hepatocellular Carcinoma) Biomarker Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top HCC (Hepatocellular Carcinoma) Biomarker Players by Revenue
3.1.1 Global Top HCC (Hepatocellular Carcinoma) Biomarker Players by Revenue (2020-2025)
3.1.2 Global HCC (Hepatocellular Carcinoma) Biomarker Revenue Market Share by Players (2020-2025)
3.2 Global HCC (Hepatocellular Carcinoma) Biomarker Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Global Key Players Ranking by HCC (Hepatocellular Carcinoma) Biomarker Revenue
3.4 Global HCC (Hepatocellular Carcinoma) Biomarker Market Concentration Ratio
3.4.1 Global HCC (Hepatocellular Carcinoma) Biomarker Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by HCC (Hepatocellular Carcinoma) Biomarker Revenue in 2024
3.5 Global Key Players of HCC (Hepatocellular Carcinoma) Biomarker Head office and Area Served
3.6 Global Key Players of HCC (Hepatocellular Carcinoma) Biomarker, Product and Application
3.7 Global Key Players of HCC (Hepatocellular Carcinoma) Biomarker, Date of Enter into This Industry
3.8 Mergers & Acquisitions, Expansion Plans
4 HCC (Hepatocellular Carcinoma) Biomarker Breakdown Data by Type
4.1 Global HCC (Hepatocellular Carcinoma) Biomarker Historic Market Size by Type (2020-2025)
4.2 Global HCC (Hepatocellular Carcinoma) Biomarker Forecasted Market Size by Type (2026-2031)
5 HCC (Hepatocellular Carcinoma) Biomarker Breakdown Data by Application
5.1 Global HCC (Hepatocellular Carcinoma) Biomarker Historic Market Size by Application (2020-2025)
5.2 Global HCC (Hepatocellular Carcinoma) Biomarker Forecasted Market Size by Application (2026-2031)
6 North America
6.1 North America HCC (Hepatocellular Carcinoma) Biomarker Market Size (2020-2031)
6.2 North America HCC (Hepatocellular Carcinoma) Biomarker Market Growth Rate by Country: 2020 VS 2024 VS 2031
6.3 North America HCC (Hepatocellular Carcinoma) Biomarker Market Size by Country (2020-2025)
6.4 North America HCC (Hepatocellular Carcinoma) Biomarker Market Size by Country (2026-2031)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe HCC (Hepatocellular Carcinoma) Biomarker Market Size (2020-2031)
7.2 Europe HCC (Hepatocellular Carcinoma) Biomarker Market Growth Rate by Country: 2020 VS 2024 VS 2031
7.3 Europe HCC (Hepatocellular Carcinoma) Biomarker Market Size by Country (2020-2025)
7.4 Europe HCC (Hepatocellular Carcinoma) Biomarker Market Size by Country (2026-2031)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific HCC (Hepatocellular Carcinoma) Biomarker Market Size (2020-2031)
8.2 Asia-Pacific HCC (Hepatocellular Carcinoma) Biomarker Market Growth Rate by Region: 2020 VS 2024 VS 2031
8.3 Asia-Pacific HCC (Hepatocellular Carcinoma) Biomarker Market Size by Region (2020-2025)
8.4 Asia-Pacific HCC (Hepatocellular Carcinoma) Biomarker Market Size by Region (2026-2031)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America HCC (Hepatocellular Carcinoma) Biomarker Market Size (2020-2031)
9.2 Latin America HCC (Hepatocellular Carcinoma) Biomarker Market Growth Rate by Country: 2020 VS 2024 VS 2031
9.3 Latin America HCC (Hepatocellular Carcinoma) Biomarker Market Size by Country (2020-2025)
9.4 Latin America HCC (Hepatocellular Carcinoma) Biomarker Market Size by Country (2026-2031)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa HCC (Hepatocellular Carcinoma) Biomarker Market Size (2020-2031)
10.2 Middle East & Africa HCC (Hepatocellular Carcinoma) Biomarker Market Growth Rate by Country: 2020 VS 2024 VS 2031
10.3 Middle East & Africa HCC (Hepatocellular Carcinoma) Biomarker Market Size by Country (2020-2025)
10.4 Middle East & Africa HCC (Hepatocellular Carcinoma) Biomarker Market Size by Country (2026-2031)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 FUJIFILM
11.1.1 FUJIFILM Company Details
11.1.2 FUJIFILM Business Overview
11.1.3 FUJIFILM HCC (Hepatocellular Carcinoma) Biomarker Introduction
11.1.4 FUJIFILM Revenue in HCC (Hepatocellular Carcinoma) Biomarker Business (2020-2025)
11.1.5 FUJIFILM Recent Development
11.2 Eli Lilly and Company
11.2.1 Eli Lilly and Company Company Details
11.2.2 Eli Lilly and Company Business Overview
11.2.3 Eli Lilly and Company HCC (Hepatocellular Carcinoma) Biomarker Introduction
11.2.4 Eli Lilly and Company Revenue in HCC (Hepatocellular Carcinoma) Biomarker Business (2020-2025)
11.2.5 Eli Lilly and Company Recent Development
11.3 Fujirebio
11.3.1 Fujirebio Company Details
11.3.2 Fujirebio Business Overview
11.3.3 Fujirebio HCC (Hepatocellular Carcinoma) Biomarker Introduction
11.3.4 Fujirebio Revenue in HCC (Hepatocellular Carcinoma) Biomarker Business (2020-2025)
11.3.5 Fujirebio Recent Development
11.4 Roche Diagnostics
11.4.1 Roche Diagnostics Company Details
11.4.2 Roche Diagnostics Business Overview
11.4.3 Roche Diagnostics HCC (Hepatocellular Carcinoma) Biomarker Introduction
11.4.4 Roche Diagnostics Revenue in HCC (Hepatocellular Carcinoma) Biomarker Business (2020-2025)
11.4.5 Roche Diagnostics Recent Development
11.5 Fapon Biotech
11.5.1 Fapon Biotech Company Details
11.5.2 Fapon Biotech Business Overview
11.5.3 Fapon Biotech HCC (Hepatocellular Carcinoma) Biomarker Introduction
11.5.4 Fapon Biotech Revenue in HCC (Hepatocellular Carcinoma) Biomarker Business (2020-2025)
11.5.5 Fapon Biotech Recent Development
11.6 Labcorp
11.6.1 Labcorp Company Details
11.6.2 Labcorp Business Overview
11.6.3 Labcorp HCC (Hepatocellular Carcinoma) Biomarker Introduction
11.6.4 Labcorp Revenue in HCC (Hepatocellular Carcinoma) Biomarker Business (2020-2025)
11.6.5 Labcorp Recent Development
11.7 Thermo Fisher Scientific
11.7.1 Thermo Fisher Scientific Company Details
11.7.2 Thermo Fisher Scientific Business Overview
11.7.3 Thermo Fisher Scientific HCC (Hepatocellular Carcinoma) Biomarker Introduction
11.7.4 Thermo Fisher Scientific Revenue in HCC (Hepatocellular Carcinoma) Biomarker Business (2020-2025)
11.7.5 Thermo Fisher Scientific Recent Development
11.8 Abcam
11.8.1 Abcam Company Details
11.8.2 Abcam Business Overview
11.8.3 Abcam HCC (Hepatocellular Carcinoma) Biomarker Introduction
11.8.4 Abcam Revenue in HCC (Hepatocellular Carcinoma) Biomarker Business (2020-2025)
11.8.5 Abcam Recent Development
11.9 Bio-Techne
11.9.1 Bio-Techne Company Details
11.9.2 Bio-Techne Business Overview
11.9.3 Bio-Techne HCC (Hepatocellular Carcinoma) Biomarker Introduction
11.9.4 Bio-Techne Revenue in HCC (Hepatocellular Carcinoma) Biomarker Business (2020-2025)
11.9.5 Bio-Techne Recent Development
11.10 MyBiosource
11.10.1 MyBiosource Company Details
11.10.2 MyBiosource Business Overview
11.10.3 MyBiosource HCC (Hepatocellular Carcinoma) Biomarker Introduction
11.10.4 MyBiosource Revenue in HCC (Hepatocellular Carcinoma) Biomarker Business (2020-2025)
11.10.5 MyBiosource Recent Development
11.11 RayBiotech
11.11.1 RayBiotech Company Details
11.11.2 RayBiotech Business Overview
11.11.3 RayBiotech HCC (Hepatocellular Carcinoma) Biomarker Introduction
11.11.4 RayBiotech Revenue in HCC (Hepatocellular Carcinoma) Biomarker Business (2020-2025)
11.11.5 RayBiotech Recent Development
11.12 CUSABIO
11.12.1 CUSABIO Company Details
11.12.2 CUSABIO Business Overview
11.12.3 CUSABIO HCC (Hepatocellular Carcinoma) Biomarker Introduction
11.12.4 CUSABIO Revenue in HCC (Hepatocellular Carcinoma) Biomarker Business (2020-2025)
11.12.5 CUSABIO Recent Development
11.13 Elabscience Biotechnology
11.13.1 Elabscience Biotechnology Company Details
11.13.2 Elabscience Biotechnology Business Overview
11.13.3 Elabscience Biotechnology HCC (Hepatocellular Carcinoma) Biomarker Introduction
11.13.4 Elabscience Biotechnology Revenue in HCC (Hepatocellular Carcinoma) Biomarker Business (2020-2025)
11.13.5 Elabscience Biotechnology Recent Development
11.14 Abbexa
11.14.1 Abbexa Company Details
11.14.2 Abbexa Business Overview
11.14.3 Abbexa HCC (Hepatocellular Carcinoma) Biomarker Introduction
11.14.4 Abbexa Revenue in HCC (Hepatocellular Carcinoma) Biomarker Business (2020-2025)
11.14.5 Abbexa Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.1.1 Research Programs/Design
13.1.1.2 Market Size Estimation
13.1.1.3 Market Breakdown and Data Triangulation
13.1.2 Data Source
13.1.2.1 Secondary Sources
13.1.2.2 Primary Sources
13.2 Author Details
13.3 Disclaimer
FEATURED COMPANIES
Fujifilm
Eli Lilly and Company
Fujirebio
Roche Diagnostics
Fapon Biotech
LabCorp
Thermo Fisher Scientific
Abcam
Bio-Techne
MyBioSource
RayBiotech
Cusabio
Elabscience Biotechnology
Abbexa
List of Tables
 Table 1. Global HCC (Hepatocellular Carcinoma) Biomarker Market Size Growth Rate by Type (US$ Million): 2020 VS 2024 VS 2031
 Table 2. Key Players of Alpha-fetoprotein (AFP)
 Table 3. Key Players of Des-γ-carboxy Prothrombin (DCP)
 Table 4. Key Players of Others
 Table 5. Global HCC (Hepatocellular Carcinoma) Biomarker Market Size Growth by Application (US$ Million): 2020 VS 2024 VS 2031
 Table 6. Global HCC (Hepatocellular Carcinoma) Biomarker Market Size by Region (US$ Million): 2020 VS 2024 VS 2031
 Table 7. Global HCC (Hepatocellular Carcinoma) Biomarker Market Size by Region (2020-2025) & (US$ Million)
 Table 8. Global HCC (Hepatocellular Carcinoma) Biomarker Market Share by Region (2020-2025)
 Table 9. Global HCC (Hepatocellular Carcinoma) Biomarker Forecasted Market Size by Region (2026-2031) & (US$ Million)
 Table 10. Global HCC (Hepatocellular Carcinoma) Biomarker Market Share by Region (2026-2031)
 Table 11. HCC (Hepatocellular Carcinoma) Biomarker Market Trends
 Table 12. HCC (Hepatocellular Carcinoma) Biomarker Market Drivers
 Table 13. HCC (Hepatocellular Carcinoma) Biomarker Market Challenges
 Table 14. HCC (Hepatocellular Carcinoma) Biomarker Market Restraints
 Table 15. Global HCC (Hepatocellular Carcinoma) Biomarker Revenue by Players (2020-2025) & (US$ Million)
 Table 16. Global HCC (Hepatocellular Carcinoma) Biomarker Market Share by Players (2020-2025)
 Table 17. Global Top HCC (Hepatocellular Carcinoma) Biomarker Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in HCC (Hepatocellular Carcinoma) Biomarker as of 2024)
 Table 18. Ranking of Global Top HCC (Hepatocellular Carcinoma) Biomarker Companies by Revenue (US$ Million) in 2024
 Table 19. Global 5 Largest Players Market Share by HCC (Hepatocellular Carcinoma) Biomarker Revenue (CR5 and HHI) & (2020-2025)
 Table 20. Global Key Players of HCC (Hepatocellular Carcinoma) Biomarker, Headquarters and Area Served
 Table 21. Global Key Players of HCC (Hepatocellular Carcinoma) Biomarker, Product and Application
 Table 22. Global Key Players of HCC (Hepatocellular Carcinoma) Biomarker, Date of Enter into This Industry
 Table 23. Mergers & Acquisitions, Expansion Plans
 Table 24. Global HCC (Hepatocellular Carcinoma) Biomarker Market Size by Type (2020-2025) & (US$ Million)
 Table 25. Global HCC (Hepatocellular Carcinoma) Biomarker Revenue Market Share by Type (2020-2025)
 Table 26. Global HCC (Hepatocellular Carcinoma) Biomarker Forecasted Market Size by Type (2026-2031) & (US$ Million)
 Table 27. Global HCC (Hepatocellular Carcinoma) Biomarker Revenue Market Share by Type (2026-2031)
 Table 28. Global HCC (Hepatocellular Carcinoma) Biomarker Market Size by Application (2020-2025) & (US$ Million)
 Table 29. Global HCC (Hepatocellular Carcinoma) Biomarker Revenue Market Share by Application (2020-2025)
 Table 30. Global HCC (Hepatocellular Carcinoma) Biomarker Forecasted Market Size by Application (2026-2031) & (US$ Million)
 Table 31. Global HCC (Hepatocellular Carcinoma) Biomarker Revenue Market Share by Application (2026-2031)
 Table 32. North America HCC (Hepatocellular Carcinoma) Biomarker Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
 Table 33. North America HCC (Hepatocellular Carcinoma) Biomarker Market Size by Country (2020-2025) & (US$ Million)
 Table 34. North America HCC (Hepatocellular Carcinoma) Biomarker Market Size by Country (2026-2031) & (US$ Million)
 Table 35. Europe HCC (Hepatocellular Carcinoma) Biomarker Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
 Table 36. Europe HCC (Hepatocellular Carcinoma) Biomarker Market Size by Country (2020-2025) & (US$ Million)
 Table 37. Europe HCC (Hepatocellular Carcinoma) Biomarker Market Size by Country (2026-2031) & (US$ Million)
 Table 38. Asia-Pacific HCC (Hepatocellular Carcinoma) Biomarker Market Size Growth Rate by Region (US$ Million): 2020 VS 2024 VS 2031
 Table 39. Asia-Pacific HCC (Hepatocellular Carcinoma) Biomarker Market Size by Region (2020-2025) & (US$ Million)
 Table 40. Asia-Pacific HCC (Hepatocellular Carcinoma) Biomarker Market Size by Region (2026-2031) & (US$ Million)
 Table 41. Latin America HCC (Hepatocellular Carcinoma) Biomarker Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
 Table 42. Latin America HCC (Hepatocellular Carcinoma) Biomarker Market Size by Country (2020-2025) & (US$ Million)
 Table 43. Latin America HCC (Hepatocellular Carcinoma) Biomarker Market Size by Country (2026-2031) & (US$ Million)
 Table 44. Middle East & Africa HCC (Hepatocellular Carcinoma) Biomarker Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
 Table 45. Middle East & Africa HCC (Hepatocellular Carcinoma) Biomarker Market Size by Country (2020-2025) & (US$ Million)
 Table 46. Middle East & Africa HCC (Hepatocellular Carcinoma) Biomarker Market Size by Country (2026-2031) & (US$ Million)
 Table 47. FUJIFILM Company Details
 Table 48. FUJIFILM Business Overview
 Table 49. FUJIFILM HCC (Hepatocellular Carcinoma) Biomarker Product
 Table 50. FUJIFILM Revenue in HCC (Hepatocellular Carcinoma) Biomarker Business (2020-2025) & (US$ Million)
 Table 51. FUJIFILM Recent Development
 Table 52. Eli Lilly and Company Company Details
 Table 53. Eli Lilly and Company Business Overview
 Table 54. Eli Lilly and Company HCC (Hepatocellular Carcinoma) Biomarker Product
 Table 55. Eli Lilly and Company Revenue in HCC (Hepatocellular Carcinoma) Biomarker Business (2020-2025) & (US$ Million)
 Table 56. Eli Lilly and Company Recent Development
 Table 57. Fujirebio Company Details
 Table 58. Fujirebio Business Overview
 Table 59. Fujirebio HCC (Hepatocellular Carcinoma) Biomarker Product
 Table 60. Fujirebio Revenue in HCC (Hepatocellular Carcinoma) Biomarker Business (2020-2025) & (US$ Million)
 Table 61. Fujirebio Recent Development
 Table 62. Roche Diagnostics Company Details
 Table 63. Roche Diagnostics Business Overview
 Table 64. Roche Diagnostics HCC (Hepatocellular Carcinoma) Biomarker Product
 Table 65. Roche Diagnostics Revenue in HCC (Hepatocellular Carcinoma) Biomarker Business (2020-2025) & (US$ Million)
 Table 66. Roche Diagnostics Recent Development
 Table 67. Fapon Biotech Company Details
 Table 68. Fapon Biotech Business Overview
 Table 69. Fapon Biotech HCC (Hepatocellular Carcinoma) Biomarker Product
 Table 70. Fapon Biotech Revenue in HCC (Hepatocellular Carcinoma) Biomarker Business (2020-2025) & (US$ Million)
 Table 71. Fapon Biotech Recent Development
 Table 72. Labcorp Company Details
 Table 73. Labcorp Business Overview
 Table 74. Labcorp HCC (Hepatocellular Carcinoma) Biomarker Product
 Table 75. Labcorp Revenue in HCC (Hepatocellular Carcinoma) Biomarker Business (2020-2025) & (US$ Million)
 Table 76. Labcorp Recent Development
 Table 77. Thermo Fisher Scientific Company Details
 Table 78. Thermo Fisher Scientific Business Overview
 Table 79. Thermo Fisher Scientific HCC (Hepatocellular Carcinoma) Biomarker Product
 Table 80. Thermo Fisher Scientific Revenue in HCC (Hepatocellular Carcinoma) Biomarker Business (2020-2025) & (US$ Million)
 Table 81. Thermo Fisher Scientific Recent Development
 Table 82. Abcam Company Details
 Table 83. Abcam Business Overview
 Table 84. Abcam HCC (Hepatocellular Carcinoma) Biomarker Product
 Table 85. Abcam Revenue in HCC (Hepatocellular Carcinoma) Biomarker Business (2020-2025) & (US$ Million)
 Table 86. Abcam Recent Development
 Table 87. Bio-Techne Company Details
 Table 88. Bio-Techne Business Overview
 Table 89. Bio-Techne HCC (Hepatocellular Carcinoma) Biomarker Product
 Table 90. Bio-Techne Revenue in HCC (Hepatocellular Carcinoma) Biomarker Business (2020-2025) & (US$ Million)
 Table 91. Bio-Techne Recent Development
 Table 92. MyBiosource Company Details
 Table 93. MyBiosource Business Overview
 Table 94. MyBiosource HCC (Hepatocellular Carcinoma) Biomarker Product
 Table 95. MyBiosource Revenue in HCC (Hepatocellular Carcinoma) Biomarker Business (2020-2025) & (US$ Million)
 Table 96. MyBiosource Recent Development
 Table 97. RayBiotech Company Details
 Table 98. RayBiotech Business Overview
 Table 99. RayBiotech HCC (Hepatocellular Carcinoma) Biomarker Product
 Table 100. RayBiotech Revenue in HCC (Hepatocellular Carcinoma) Biomarker Business (2020-2025) & (US$ Million)
 Table 101. RayBiotech Recent Development
 Table 102. CUSABIO Company Details
 Table 103. CUSABIO Business Overview
 Table 104. CUSABIO HCC (Hepatocellular Carcinoma) Biomarker Product
 Table 105. CUSABIO Revenue in HCC (Hepatocellular Carcinoma) Biomarker Business (2020-2025) & (US$ Million)
 Table 106. CUSABIO Recent Development
 Table 107. Elabscience Biotechnology Company Details
 Table 108. Elabscience Biotechnology Business Overview
 Table 109. Elabscience Biotechnology HCC (Hepatocellular Carcinoma) Biomarker Product
 Table 110. Elabscience Biotechnology Revenue in HCC (Hepatocellular Carcinoma) Biomarker Business (2020-2025) & (US$ Million)
 Table 111. Elabscience Biotechnology Recent Development
 Table 112. Abbexa Company Details
 Table 113. Abbexa Business Overview
 Table 114. Abbexa HCC (Hepatocellular Carcinoma) Biomarker Product
 Table 115. Abbexa Revenue in HCC (Hepatocellular Carcinoma) Biomarker Business (2020-2025) & (US$ Million)
 Table 116. Abbexa Recent Development
 Table 117. Research Programs/Design for This Report
 Table 118. Key Data Information from Secondary Sources
 Table 119. Key Data Information from Primary Sources
 Table 120. Authors List of This Report


List of Figures
 Figure 1. HCC (Hepatocellular Carcinoma) Biomarker Picture
 Figure 2. Global HCC (Hepatocellular Carcinoma) Biomarker Market Size Comparison by Type (2020-2031) & (US$ Million)
 Figure 3. Global HCC (Hepatocellular Carcinoma) Biomarker Market Share by Type: 2024 VS 2031
 Figure 4. Alpha-fetoprotein (AFP) Features
 Figure 5. Des-γ-carboxy Prothrombin (DCP) Features
 Figure 6. Others Features
 Figure 7. Global HCC (Hepatocellular Carcinoma) Biomarker Market Size by Application (2020-2031) & (US$ Million)
 Figure 8. Global HCC (Hepatocellular Carcinoma) Biomarker Market Share by Application: 2024 VS 2031
 Figure 9. Hospitals Case Studies
 Figure 10. Clinics Case Studies
 Figure 11. Others Case Studies
 Figure 12. HCC (Hepatocellular Carcinoma) Biomarker Report Years Considered
 Figure 13. Global HCC (Hepatocellular Carcinoma) Biomarker Market Size (US$ Million), Year-over-Year: 2020-2031
 Figure 14. Global HCC (Hepatocellular Carcinoma) Biomarker Market Size, (US$ Million), 2020 VS 2024 VS 2031
 Figure 15. Global HCC (Hepatocellular Carcinoma) Biomarker Market Share by Region: 2024 VS 2031
 Figure 16. Global HCC (Hepatocellular Carcinoma) Biomarker Market Share by Players in 2024
 Figure 17. Global Top HCC (Hepatocellular Carcinoma) Biomarker Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in HCC (Hepatocellular Carcinoma) Biomarker as of 2024)
 Figure 18. The Top 10 and 5 Players Market Share by HCC (Hepatocellular Carcinoma) Biomarker Revenue in 2024
 Figure 19. North America HCC (Hepatocellular Carcinoma) Biomarker Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 20. North America HCC (Hepatocellular Carcinoma) Biomarker Market Share by Country (2020-2031)
 Figure 21. United States HCC (Hepatocellular Carcinoma) Biomarker Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 22. Canada HCC (Hepatocellular Carcinoma) Biomarker Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 23. Europe HCC (Hepatocellular Carcinoma) Biomarker Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 24. Europe HCC (Hepatocellular Carcinoma) Biomarker Market Share by Country (2020-2031)
 Figure 25. Germany HCC (Hepatocellular Carcinoma) Biomarker Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 26. France HCC (Hepatocellular Carcinoma) Biomarker Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 27. U.K. HCC (Hepatocellular Carcinoma) Biomarker Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 28. Italy HCC (Hepatocellular Carcinoma) Biomarker Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 29. Russia HCC (Hepatocellular Carcinoma) Biomarker Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 30. Nordic Countries HCC (Hepatocellular Carcinoma) Biomarker Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 31. Asia-Pacific HCC (Hepatocellular Carcinoma) Biomarker Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 32. Asia-Pacific HCC (Hepatocellular Carcinoma) Biomarker Market Share by Region (2020-2031)
 Figure 33. China HCC (Hepatocellular Carcinoma) Biomarker Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 34. Japan HCC (Hepatocellular Carcinoma) Biomarker Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 35. South Korea HCC (Hepatocellular Carcinoma) Biomarker Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 36. Southeast Asia HCC (Hepatocellular Carcinoma) Biomarker Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 37. India HCC (Hepatocellular Carcinoma) Biomarker Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 38. Australia HCC (Hepatocellular Carcinoma) Biomarker Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 39. Latin America HCC (Hepatocellular Carcinoma) Biomarker Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 40. Latin America HCC (Hepatocellular Carcinoma) Biomarker Market Share by Country (2020-2031)
 Figure 41. Mexico HCC (Hepatocellular Carcinoma) Biomarker Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 42. Brazil HCC (Hepatocellular Carcinoma) Biomarker Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 43. Middle East & Africa HCC (Hepatocellular Carcinoma) Biomarker Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 44. Middle East & Africa HCC (Hepatocellular Carcinoma) Biomarker Market Share by Country (2020-2031)
 Figure 45. Turkey HCC (Hepatocellular Carcinoma) Biomarker Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 46. Saudi Arabia HCC (Hepatocellular Carcinoma) Biomarker Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 47. UAE HCC (Hepatocellular Carcinoma) Biomarker Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 48. FUJIFILM Revenue Growth Rate in HCC (Hepatocellular Carcinoma) Biomarker Business (2020-2025)
 Figure 49. Eli Lilly and Company Revenue Growth Rate in HCC (Hepatocellular Carcinoma) Biomarker Business (2020-2025)
 Figure 50. Fujirebio Revenue Growth Rate in HCC (Hepatocellular Carcinoma) Biomarker Business (2020-2025)
 Figure 51. Roche Diagnostics Revenue Growth Rate in HCC (Hepatocellular Carcinoma) Biomarker Business (2020-2025)
 Figure 52. Fapon Biotech Revenue Growth Rate in HCC (Hepatocellular Carcinoma) Biomarker Business (2020-2025)
 Figure 53. Labcorp Revenue Growth Rate in HCC (Hepatocellular Carcinoma) Biomarker Business (2020-2025)
 Figure 54. Thermo Fisher Scientific Revenue Growth Rate in HCC (Hepatocellular Carcinoma) Biomarker Business (2020-2025)
 Figure 55. Abcam Revenue Growth Rate in HCC (Hepatocellular Carcinoma) Biomarker Business (2020-2025)
 Figure 56. Bio-Techne Revenue Growth Rate in HCC (Hepatocellular Carcinoma) Biomarker Business (2020-2025)
 Figure 57. MyBiosource Revenue Growth Rate in HCC (Hepatocellular Carcinoma) Biomarker Business (2020-2025)
 Figure 58. RayBiotech Revenue Growth Rate in HCC (Hepatocellular Carcinoma) Biomarker Business (2020-2025)
 Figure 59. CUSABIO Revenue Growth Rate in HCC (Hepatocellular Carcinoma) Biomarker Business (2020-2025)
 Figure 60. Elabscience Biotechnology Revenue Growth Rate in HCC (Hepatocellular Carcinoma) Biomarker Business (2020-2025)
 Figure 61. Abbexa Revenue Growth Rate in HCC (Hepatocellular Carcinoma) Biomarker Business (2020-2025)
 Figure 62. Bottom-up and Top-down Approaches for This Report
 Figure 63. Data Triangulation
 Figure 64. Key Executives Interviewed
SELECT A FORMAT
Added to Cart
Electronic (PDF)

$2900

This license allows only one user to access the PDF.
Electronic (PDF)

$4350

This license allows 1 - 5 user to access the PDF, license is suitable for small groups of 5 users working together
Electronic (PDF)

$5800

This license allows users/teams in a same Enterprise to use this report, various departments within an enterpise can use this report
Add to Cart
Buy Now (15% Discount)
INQUIRE FOR DISCOUNT

HAVE A QUERY?

INQUIRE ABOUT REPORT EMAIL US

OUR CUSTOMER

Lukasiewicz Research Network

SIMILAR REPORTS

Global HCC Biomarker Market Research Report 2024
Global Alpha Fetoprotein AFP Biomarker Market Research Report 2024
Global Hepatocellular Carcinoma Targeted Drug Market Research Report 2025
Global Hepatoma Cell Targeted Drug Market Research Report 2025
Hepatocellular Carcinoma Treatment Drug Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Global Liver Cancer Molecular Diagnostics Market Research Report 2024
Global Liver Cancer Therapeutics Market Insights Forecast to 2030
Liver Cancer Diagnostics Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Global Hepatocellular Carcinoma Monoclonal Antibody Market Research Report 2025
Global Unresectable Hepatocellular Carcinoma Treatment Market Research Report 2024
Global Liver Cancer Treatment Drug Market Research Report 2025
Global Diagnostic Biomarker Market Research Report 2024
Non Alcoholic Steatohepatitis Biomarkers Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Global Advanced Liver Cancer Treatment Drugs Market Research Report 2024
Liver Cancer Diagnostic Tests Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Global Non alcoholic Steatohepatitis NASH Biomarkers Market Research Report 2024
Global Clinical Biomarker Testing Market Research Report 2024
Global Commercializing Biomarkers Market Research Report 2025
Global Clinical Biomarkers Market Research Report 2024
Global Mouse Model Market Research Report 2024

RELATED REPORTS

Global Radioactive Iodine Ablation Therapy Market Research Report 2025

120 Pages
Type: Report
Code: QYRE-Auto-9U20281
Tue Dec 02 00:00:00 UTC 2025

Add to Cart

Global AI Contouring Software for Radiotherapy Market Research Report 2025

120 Pages
Type: Report
Code: QYRE-Auto-32T20006
Thu Nov 27 00:00:00 UTC 2025

Add to Cart

Global Cell Senescence β-Galactosidase Staining Kit Market Research Report 2025

120 Pages
Type: Report
Code: QYRE-Auto-0Q20500
Thu Nov 27 00:00:00 UTC 2025

Add to Cart

Global Kinase Inhibitors For Cancer Treatment Market Outlook, In‑Depth Analysis & Forecast to 2031

120 Pages
Type: Report
Code: QYRE-Auto-18V16958
Wed Nov 12 00:00:00 UTC 2025

Add to Cart

Call
Buy Now
REQUEST FREE SAMPLE REPORT
Support Contacts
U.S. (TOLL FREE)
+1 (425) 388-2538
THE COMPANY
OUR PRODUCTS
CUSTOMER SUPPORT
POLICES
THE COMPANY
CUSTOMER SUPPORT
OUR PRODUCTS
POLICES
Copyright © 2018 Valuates.com. All Rights Reserved.
Sitemap - Privacy Policy - Terms & Conditions